IN2014DN10550A - - Google Patents

Info

Publication number
IN2014DN10550A
IN2014DN10550A IN10550DEN2014A IN2014DN10550A IN 2014DN10550 A IN2014DN10550 A IN 2014DN10550A IN 10550DEN2014 A IN10550DEN2014 A IN 10550DEN2014A IN 2014DN10550 A IN2014DN10550 A IN 2014DN10550A
Authority
IN
India
Prior art keywords
cerium oxide
multiple sclerosis
oxide nanoparticles
biocompatible
nanoparticles
Prior art date
Application number
Inventor
Kenneth Joseph Reed
Wendi Ann Costanzo
Joseph Samuel Erlichman
Eric Leslie Bell
Original Assignee
Cerion Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerion Entpr Llc filed Critical Cerion Entpr Llc
Publication of IN2014DN10550A publication Critical patent/IN2014DN10550A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)

Abstract

A process for making nanoparticles of biocompatible materials is described wherein an aqueous reaction mixture comprising cerous ion citric acid and ethylenediaminetetraacetic acid in a predetermined ratio an oxidant and water is provided along with temperature conditions to directly form without isolation a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases such as stroke relapse/remitting multiple sclerosis chronic progressive multiple sclerosis amyotrophic lateral sclerosis and ischemic reperfusion injury.
IN10550DEN2014 2012-06-13 2013-03-15 IN2014DN10550A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261689806P 2012-06-13 2012-06-13
US201261690100P 2012-06-18 2012-06-18
US201261795241P 2012-10-12 2012-10-12
US201261796639P 2012-11-16 2012-11-16
PCT/US2013/032318 WO2013187980A1 (en) 2012-06-13 2013-03-15 Nanoceria for the treatment of oxidative stress

Publications (1)

Publication Number Publication Date
IN2014DN10550A true IN2014DN10550A (en) 2015-08-21

Family

ID=48048227

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10550DEN2014 IN2014DN10550A (en) 2012-06-13 2013-03-15

Country Status (12)

Country Link
US (4) US9034392B2 (en)
EP (1) EP2861212B1 (en)
JP (1) JP6174692B2 (en)
KR (1) KR101990070B1 (en)
CN (1) CN104812375B (en)
AU (1) AU2013274901B2 (en)
CA (1) CA2875206C (en)
DK (1) DK2861212T3 (en)
ES (1) ES2617528T3 (en)
IN (1) IN2014DN10550A (en)
MX (1) MX2014015251A (en)
WO (1) WO2013187980A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10550A (en) 2012-06-13 2015-08-21 Cerion Entpr Llc
US9446070B2 (en) * 2012-06-13 2016-09-20 Cerion, Llc Nanoceria with citric acid additive
AU2014256983B2 (en) 2013-04-25 2018-10-04 Cerion Enterprises, Llc Chelated nanoceria for the treatment of oxidative stress
US10182994B2 (en) * 2014-06-10 2019-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoparticulate complex of nicotine and cerium oxide and use thereof
BR112017000800A8 (en) * 2014-07-17 2023-04-25 Biocurity Holdings Inc CANCER TREATMENT WITH A COMBINATION OF RADIATION, CERION OXIDE NANOPARTICLES, AND A CHEMOTHERAPY AGENT
JP2018508568A (en) 2015-01-20 2018-03-29 セリオン，リミティド ライアビリティ カンパニー Nanoceria chelated with EDDS with catalase-like activity
KR101765557B1 (en) 2015-02-27 2017-08-23 서울대학교산학협력단 Bioresorbable Electronic Stent
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
EP3380088A4 (en) * 2015-11-25 2019-07-31 The Regents of the University of Colorado, A Body Corporate USE OF MICROARN-146A AND A CONJUGATE OF CERIUM OXIDE NANOPARTICLES TO IMPROVE HEALING AND PROMOTE TISSUE REGENERATION
AU2017384425B2 (en) * 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
AU2018390163B2 (en) 2017-12-19 2024-05-02 Nanobiotix Nanoparticles for use in enhancing brain performances or in treating stress
HUE068741T2 (en) 2017-12-19 2025-01-28 Nanobiotix Nanoparticles for use for treating a neuronal disorder
WO2020069292A1 (en) * 2018-09-28 2020-04-02 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
CN111333098B (en) * 2018-11-30 2022-04-19 中国科学院大连化学物理研究所 Preparation method of cerium dioxide nano cube
CN109806278B (en) * 2019-02-01 2021-08-10 浙江大学 Application of phospholipid polyethylene glycol modified subminiature cerium oxide nanocrystal
FR3093640B1 (en) * 2019-03-15 2021-10-01 Biophytis Phytoecdysones and their derivatives for their use in the treatment of neuromuscular diseases
CN109939125B (en) * 2019-04-22 2021-05-18 南昌大学第二附属医院 A kind of antioxidant and its preparation method and application
FR3098723B1 (en) * 2019-07-18 2023-01-13 Bionuclei ECOBIOLOGICAL TREATMENT OF SIDE EFFECTS OF RADIOTHERAPY.
KR102107760B1 (en) * 2019-08-28 2020-05-07 한국콜마주식회사 Dispersion of cerium oxide for enhancing skin barrier, skin moisturizing, and/or protecting microdust, and, cosmetic composition comprising the same
JP7740020B2 (en) * 2020-05-27 2025-09-17 東レ株式会社 Cerium oxide nanoparticles, antibacterial agents, antiviral agents, and method for producing cerium oxide nanoparticles
CN111773243B (en) * 2020-07-17 2022-09-23 南京大学 Medicine for inflammatory bowel disease and preparation method and application thereof
CN112007016B (en) * 2020-09-07 2021-07-23 南京大学 A nano sustained-release preparation, its preparation method and its application in the preparation of a medicine for treating mitochondrial dysfunction diseases
CN112494513A (en) * 2020-12-15 2021-03-16 中国药科大学 Cerium dioxide nanoparticles and preparation method and application thereof
CN112516294B (en) * 2020-12-22 2023-04-07 浙江大学 Application of cerium oxide nano stabilizer in preparation of medicine for preventing allergic diseases and medicine composition for preventing allergic diseases
CN113546093A (en) * 2021-07-20 2021-10-26 中国人民解放军陆军军医大学 Application of cerium oxide nanoparticles in the preparation of drugs for the treatment and prevention of renal ischemia-reperfusion injury
CN113842469B (en) * 2021-08-25 2024-04-02 中国科学院过程工程研究所 A drug delivery system of in-situ crystallized cerium nanocrystals with high catalytic activity on the surface of vesicles, and its preparation method and application
CN114470326B (en) * 2021-12-06 2022-09-13 中国人民解放军空军军医大学 Preparation method and application of biomimetic mineralized collagen-glycosaminoglycan material
KR102810481B1 (en) * 2022-01-21 2025-05-19 성균관대학교산학협력단 Vaccine for Treating Multiple Sclerosis
US12521414B2 (en) * 2022-06-08 2026-01-13 National Health Research Institutes Method for preventing or treating urological chronic pelvic pain syndrome
CN116270729A (en) * 2022-11-09 2023-06-23 西安交通大学医学院第一附属医院 Application of porous nanorod-shaped cerium oxide in preparation of medicine for treating atopic dermatitis
CN115737678B (en) * 2022-11-30 2024-12-20 浙江大学金华研究院 Liposome gel carrying triphenylphosphine modified cerium oxide and all-trans retinoic acid
CN116180065B (en) * 2022-12-27 2024-10-08 国科大杭州高等研究院 Surface modified nickel-titanium alloy material and preparation method and application thereof
CN116036127B (en) * 2023-01-17 2025-09-23 中国人民解放军陆军军医大学 Application of cerium oxide nanoclusters in improving chronic kidney disease
AU2023424695A1 (en) * 2023-01-18 2025-08-28 Applause Pharma Co., Ltd. Pharmaceutical composition having, as active ingredient, cerium compound that contains trivalent cerium
CN116850147B (en) * 2023-06-05 2024-05-14 中南大学 PPC nanoparticles, preparation method thereof and application in medicine for treating myocardial infarction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809637B1 (en) 2000-06-05 2003-01-24 Rhodia Terres Rares COLLOIDAL DISPERSION OF A CERIUM COMPOUND OR A CERIUM COMPOUND AND AT LEAST ONE OTHER ELEMENT SELECTED AMONG RARE EARTHS AND TRANSITION METALS, INCLUDING AN AMINO ACID
JP3768401B2 (en) 2000-11-24 2006-04-19 Ｎｅｃエレクトロニクス株式会社 Chemical mechanical polishing slurry
JP3586711B2 (en) 2000-12-27 2004-11-10 独立行政法人物質・材料研究機構 Method for producing nanoceria powder
JP3793802B2 (en) 2001-07-09 2006-07-05 独立行政法人物質・材料研究機構 Production method of ceria powder with individual particles separated into nano size
US7563457B2 (en) 2001-10-02 2009-07-21 The Regents Of The University Of California Nanoparticle assembled hollow spheres
US7534453B1 (en) 2002-09-05 2009-05-19 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticles and use in enhancing cell survivability
KR100486959B1 (en) * 2003-01-29 2005-05-03 한국화학연구원 Preparation method of ceria particles with nano-size
EP1765280A1 (en) 2004-06-28 2007-03-28 Procyte Corporation Methods and compositions for preventing and treating hyperpigmentation of skin
WO2007002662A2 (en) 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
WO2008002323A2 (en) 2005-12-23 2008-01-03 Eastman Kodak Company Production of cerium containing metal oxide grains
WO2008030815A2 (en) * 2006-09-05 2008-03-13 Cerion Technology, Inc. Method of preparing cerium dioxide nanoparticles
WO2009012425A2 (en) 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
DE102007062571A1 (en) 2007-12-22 2009-06-25 Evonik Degussa Gmbh Ceria and phyllosilicate-containing dispersion
CN101683999A (en) * 2008-09-26 2010-03-31 杜小青 Preparation method of nanometer cerium dioxide
CN102281945A (en) * 2008-12-17 2011-12-14 丝润技术有限公司 Fuel additive containing lattice engineered cerium dioxide nanoparticles
US8679344B2 (en) 2008-12-17 2014-03-25 Cerion Technology, Inc. Process for solvent shifting a nanoparticle dispersion
IN2014DN10550A (en) 2012-06-13 2015-08-21 Cerion Entpr Llc

Also Published As

Publication number Publication date
JP2015525228A (en) 2015-09-03
WO2013187980A1 (en) 2013-12-19
US20180250333A1 (en) 2018-09-06
JP6174692B2 (en) 2017-08-02
US9962406B2 (en) 2018-05-08
CN104812375B (en) 2017-08-22
EP2861212A1 (en) 2015-04-22
KR101990070B1 (en) 2019-06-17
AU2013274901A1 (en) 2014-12-18
US20130337083A1 (en) 2013-12-19
AU2013274901B2 (en) 2017-09-14
ES2617528T3 (en) 2017-06-19
US20150231174A1 (en) 2015-08-20
US9533007B2 (en) 2017-01-03
CA2875206C (en) 2020-07-14
MX2014015251A (en) 2015-04-13
KR20150028293A (en) 2015-03-13
DK2861212T3 (en) 2017-03-06
CA2875206A1 (en) 2013-12-19
CN104812375A (en) 2015-07-29
US9034392B2 (en) 2015-05-19
US20170100430A1 (en) 2017-04-13
US10729717B2 (en) 2020-08-04
EP2861212B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
IN2014DN10550A (en)
PH12019501662A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
BR112014013481A2 (en) process for the oxidation of alkanes with the use of an alkane alkane 1-monooxygenase
BR112015002372A2 (en) compositions and methods for reducing blood alcohol content
EP2665697A2 (en) Process for the hydration of mixed butenes to produce mixed alcohols
MX378180B (en) Composition for hair frizz reduction
WO2013158744A3 (en) Nanoparticles of cerium and amino acids
BR112014002940A2 (en) use and agrochemical composition of carboxylic acid dibutylamides
IN2014MN01552A (en)
IN2014DN06537A (en)
WO2013024013A3 (en) Process for the preparation of complexes of 68ga.
MY166900A (en) Anti-ageing composition containing dehydrogenated abietic acid as active ingredient
IN2014MN01469A (en)
IN2012DE00497A (en)
GB2512777A (en) Fatty acid ester compositions for use as emollients
MX2015005406A (en) Hydrogenation of isohexide products for improved color.
WO2011146167A3 (en) Hydroalkylation processes
WO2014016352A3 (en) Process
BR112014017587A8 (en) Methods and Formulations for the Treatment of Sialic Acid Deficiencies
HK1223559A1 (en) Formulation for gonadotropins
IN2015DN03169A (en)
NZ615623A (en) Chemical composition with hydrogen peroxide and a nanoemulsion of long-chained alcohols
AR098023A1 (en) A PROCESS TO PREPARE ISOXAFLUTOL
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
BR112015023146A2 (en) recombinant yeast and method for producing ethanol using it